Celgene has made four appointments to its senior leadership team in a reshuffle intended to position the company for continued long-term growth.
Mark Alles has been promoted to chief executive officer, effective 1 March, moving from his current role as president and chief operating officer.
With over thirty years of industry experience, Alles has been with Celgene since 2004 and has been overseeing the integration of Celgene’s corporate operational functions in support of its global commercial franchises.
Meanwhile, Celgene’s current chairman and chief executive officer Bob Hugin (pictured left) will take on the role of executive chairman, effective 1 March. He will continue to lead the company’s board of directors and manage its strategic direction.
Michael Casey, Celgene’s lead independent director, said: “As CEO, Bob has delivered exceptional results and we are incredibly grateful that Bob will continue to lead the strategic direction of Celgene.
“In addition to being involved in key business matters, as executive chairman, Bob will increase his focus on the development of Celgene’s next generation of leaders, his advocacy work to improve patient access and outcomes and on identifying the next wave of novel therapies for Celgene investment.”
Jacqualyn Fouse has also been promoted and will take on the roles of president and chief operating officer in March.
Fouse joined the company in 2010 as chief financial officer and has since served as president of Celgene’s haematology and oncology franchise, which, along with its I&I franchise, will continue to report to Fouse in her new role.
Scott Smith, currently president of Celgene’s I&I franchise, has been appointed chair of the company’s global management committee, effective 1 March.
Joining Celgene in 2008, Scott has been responsible for the development and direction of the I&I franchise and will add to this the coordination of Celgene’s operational and strategic imperatives.
Bob Hugin said: “The elevation of exceptional leaders like Mark, Jackie and Scott will strengthen our organisation and energise our operations allowing us to more fully realise our incredible potential, both benefiting Celgene and the patients that we serve.”